Sebastian Szmit: Advances in Managing Cancer-Associated Thromboembolism
OncoDaily shared on LinkedIn:
”Dr. Sebastian Szmit Highlights Advances in Managing Cancer-Associated Thromboembolism at GCOS 2025
Dr. Sebastian Szmit, from the Institute of Hematology and Transfusion Medicine and the Center of Postgraduate Medical Education in Warsaw, delivered an engaging talk on cancer-associated thromboembolism. He discussed premature mortality linked to VTE in cancer patients and reviewed ESC guideline–based anticoagulation options, comparing DOACs (apixaban, edoxaban, rivaroxaban) with low-molecular-weight heparin (LMWH). He emphasized that while DOACs are effective, LMWH remains preferred in gastrointestinal cancers due to higher bleeding risks.
Dr. Szmit also presented findings from the APICAT study, which showed that a reduced dose of apixaban can maintain efficacy while lowering bleeding risk during extended anticoagulation. He highlighted challenges such as drug interactions, thrombocytopenia, and the need for improved primary prophylaxis strategies tailored to cancer therapy.”
Stay informed with Hemostasis Today.
-
May 7, 2026, 07:21Britta Diebel: Reflections on Healthcare Impact from the PPTA IPPC Congress
-
May 7, 2026, 07:02Ana Cláudia de Souza: NeuroLeadership, Management and Behavioural Insights in Stroke Care from ESOC 2026
-
May 7, 2026, 07:00Maxime Dely: Just 60 Minutes of Our Time to Help a Patient We Will Never Meet
-
May 7, 2026, 06:37Anagha Kulkarni: Insights and A Prize from ISBMT Annual Conference 2026
-
May 7, 2026, 06:37Neelmani Singh: Why Iron Deficiency Is a Brain Health Issue
-
May 7, 2026, 06:25Vivek Sinha: The Science Behind a CBC Test
-
May 7, 2026, 06:17Emily Brown: Honor to Represent Hemophilia of Georgia at 2026 World Federation of Hemophilia Congress
-
May 7, 2026, 06:08Abdelaziz Fahem: INNOVHEM Reports a New Direct Method for Evaluating Hemolytic Anemia
-
May 7, 2026, 06:02Derick Rugenga: Every Person Living with Haemophilia Deserves to Live Without Fear